Credit Suisse’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-216,373
| Closed | -$2.69M | – | 4277 |
|
|
2016
Q4 | $2.69M | Buy |
216,373
+25,356
| +13% | +$305K | ﹤0.01% | 2190 |
|
|
2016
Q3 | $2.62M | Sell |
191,017
-98,179
| -34% | -$986K | ﹤0.01% | 2181 |
|
|
2016
Q2 | $2.14M | Buy |
289,196
+18,624
| +7% | +$140K | ﹤0.01% | 2288 |
|
|
2016
Q1 | $1.73M | Buy |
270,572
+120,302
| +80% | +$674K | ﹤0.01% | 2315 |
|
|
2015
Q4 | $939K | Sell |
150,270
-367,292
| -71% | -$2.41M | ﹤0.01% | 2866 |
|
|
2015
Q3 | $3.02M | Sell |
517,562
-131,234
| -20% | -$1.01M | ﹤0.01% | 1961 |
|
|
2015
Q2 | $5.37M | Buy |
648,796
+55,216
| +9% | +$488K | 0.01% | 1675 |
|
|
2015
Q1 | $4.89M | Buy |
593,580
+187,324
| +46% | +$1.38M | ﹤0.01% | 1686 |
|
|
2014
Q4 | $2.79M | Buy |
406,256
+15,609
| +4% | +$97.6K | ﹤0.01% | 2258 |
|
|
2014
Q3 | $2.11M | Sell |
390,647
-18,104
| -4% | -$106K | ﹤0.01% | 2444 |
|
|
2014
Q2 | $2.6M | Buy |
408,751
+31,506
| +8% | +$217K | ﹤0.01% | 2499 |
|
|
2014
Q1 | $3.04M | Sell |
377,245
-19,831
| -5% | -$154K | ﹤0.01% | 2185 |
|
|
2013
Q4 | $2.71M | Sell |
397,076
-123,482
| -24% | -$667K | ﹤0.01% | 2393 |
|
|
2013
Q3 | $9.58M | Buy |
520,558
+98,875
| +23% | +$1.92M | 0.01% | 1168 |
|
|
2013
Q2 | $7.38M | Buy |
+421,683
| New | +$7.48M | 0.01% | 1325 |
|
Other funds holding ARIA
Credit Suisse's ARIA Position: Q1 2017 in Review
Credit Suisse sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 216,373 shares — an estimated $2.69M sold.
Credit Suisse first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $9.58M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- Credit Suisse reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- Credit Suisse sold 216,373 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $2.69M.
- Credit Suisse first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Credit Suisse's Ariad Pharmaceuticals Inc position peaked at $9.58M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on Credit Suisse's 13F filing for Q1 2017, filed 15 May 2017.